Ocular Therapeutix (OCUL) Current Leases (2019 - 2026)

Ocular Therapeutix's Current Leases history runs 8 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• On a quarterly basis, Current Leases rose 47.03% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 47.03% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, up 45.73% from the prior year.
• Current Leases improved to $3.2 million in Q1 2026 per OCUL's latest filing, from $2.8 million in the prior quarter.
• Across five years, Current Leases topped out at $3.2 million in Q1 2026 and bottomed at $1.5 million in Q1 2024.
• The 5-year median for Current Leases is $1.8 million (2022), against an average of $2.0 million.
• Across the five-year window, Current Leases retreated 15.18% in 2024 and surged 60.86% in 2025, its largest moves.
• Year by year, Current Leases stood at $1.6 million in 2022, then slipped by 0.81% to $1.6 million in 2023, then rose by 21.88% to $1.9 million in 2024, then soared by 45.73% to $2.8 million in 2025, then advanced by 12.53% to $3.2 million in 2026.
• Per Business Quant, the three latest OCUL Current Leases figures stand at $3.2 million (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025).